Modulation of large- and small-conductance Ca2+-activated K+ channels (BKCa and SKCa) offers potential therapeutic benefits for cardioprotection against ischemic injury, arrhythmia, and heart failure.
Modulation of cardiomyocyte and endothelial SKCa and BKCa channels represents a promising therapeutic target for cardioprotection against ischemic injury, heart failure, and arrhythmias.
Small- and large-conductance Ca(2+)-activated K(+)channels (SKCa and BKCa, respectively) may be important targets for therapeutic interventions in a variety of cardiac conditions. In cardiomyocytes, BKCa channels are localized to mitochondria where they beneficially modulate reactive oxygen species, mitochondrial Ca(2+), and respiration. In vascular smooth muscle cells, BKCa channels regulate vascular tone and promote vasodilation. Activation of BKCa channels has demonstrated significant cardioprotection following ischemic injury, including improved function and reduced infarct size. SKCa channels are expressed in both the membrane and mitochondria of cardiomyocytes. Modulation of cardiomyocyte SKCa channels may be beneficial for arrhythmia, heart failure, and ischemia. Mitochondrial SKCa channels may provide similar benefit to BKCa channels. In addition, activation of SKCa channels on the endothelium promotes vasodilation. This mini-review focuses on the modulation of cardiomyocyte BKCa and SKCa channels for cardioprotection and briefly address associated potential therapeutic benefits in the coronary circulation.
Clements et al. (Thu,) conducted a review in Myocardial ischemia, arrhythmia, and vascular dysfunction. BKCa and SKCa channel modulators was evaluated. Modulation of large- and small-conductance Ca2+-activated K+ channels (BKCa and SKCa) offers potential therapeutic benefits for cardioprotection against ischemic injury, arrhythmia, and heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: